MX387648B - Derivados de heteroarilo tieno[3,2-d]pirimidina-6-carboxamida de la fórmula (ii) que presentan actividad inhibitoria sobre cinasa cdk4/6. - Google Patents

Derivados de heteroarilo tieno[3,2-d]pirimidina-6-carboxamida de la fórmula (ii) que presentan actividad inhibitoria sobre cinasa cdk4/6.

Info

Publication number
MX387648B
MX387648B MX2018013573A MX2018013573A MX387648B MX 387648 B MX387648 B MX 387648B MX 2018013573 A MX2018013573 A MX 2018013573A MX 2018013573 A MX2018013573 A MX 2018013573A MX 387648 B MX387648 B MX 387648B
Authority
MX
Mexico
Prior art keywords
cdk4
thieno
pyrimidine
heteroaryl
kinase
Prior art date
Application number
MX2018013573A
Other languages
English (en)
Spanish (es)
Other versions
MX2018013573A (es
Inventor
Jing Sun
Lijun Yang
Ling Chen
Min Lin
Rui Tan
Tongshuang Li
Weibo Wang
Xianlong Wang
Xingdong Zhao
Yanxin Liu
Zhifang Chen
Zuwen Zhou
Original Assignee
Fochon Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fochon Pharmaceuticals Ltd filed Critical Fochon Pharmaceuticals Ltd
Publication of MX2018013573A publication Critical patent/MX2018013573A/es
Publication of MX387648B publication Critical patent/MX387648B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
MX2018013573A 2016-05-07 2017-05-05 Derivados de heteroarilo tieno[3,2-d]pirimidina-6-carboxamida de la fórmula (ii) que presentan actividad inhibitoria sobre cinasa cdk4/6. MX387648B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662333165P 2016-05-07 2016-05-07
PCT/CN2017/083162 WO2017193872A1 (en) 2016-05-07 2017-05-05 Certain protein kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2018013573A MX2018013573A (es) 2019-08-01
MX387648B true MX387648B (es) 2025-03-18

Family

ID=60266275

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013573A MX387648B (es) 2016-05-07 2017-05-05 Derivados de heteroarilo tieno[3,2-d]pirimidina-6-carboxamida de la fórmula (ii) que presentan actividad inhibitoria sobre cinasa cdk4/6.

Country Status (13)

Country Link
US (1) US10835535B2 (cg-RX-API-DMAC7.html)
EP (1) EP3452484B1 (cg-RX-API-DMAC7.html)
JP (1) JP6927548B2 (cg-RX-API-DMAC7.html)
KR (1) KR102374033B1 (cg-RX-API-DMAC7.html)
CN (1) CN109153686B (cg-RX-API-DMAC7.html)
AU (1) AU2017262155B2 (cg-RX-API-DMAC7.html)
DK (1) DK3452484T3 (cg-RX-API-DMAC7.html)
ES (1) ES2954148T3 (cg-RX-API-DMAC7.html)
MX (1) MX387648B (cg-RX-API-DMAC7.html)
RU (1) RU2738837C2 (cg-RX-API-DMAC7.html)
TW (1) TWI752026B (cg-RX-API-DMAC7.html)
WO (1) WO2017193872A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201808238B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019161224A1 (en) 2018-02-15 2019-08-22 GiraFpharma LLC Heterocyclic compounds as kinase inhibitors
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
CN116836177A (zh) * 2022-09-28 2023-10-03 锦州奥鸿药业有限责任公司 一种蛋白激酶抑制剂的枸橼酸盐、其晶型、制备方法和用途
WO2025085360A1 (en) 2023-10-16 2025-04-24 The Board Of Regents Of The University Of Oklahoma Heteroarotinoids and/or cdk4/6 inhibitors for treating human papillomavirus (hpv)-induced dysplasias, warts, and cancer in hpv-infected subjects
US20260209246A1 (en) * 2025-01-23 2026-07-23 Incyte Corporation Furanyl or thienyl pyrimidines as cdk4 inhibitors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
US6277985B1 (en) 1995-09-15 2001-08-21 Pharmacia & Upjohn Company Aminoaryl oxazolidinone N-oxides
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
ES2294494T3 (es) 2004-04-19 2008-04-01 Symed Labs Limited Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados.
EP1768967B1 (en) 2004-07-20 2009-04-22 Symed Labs Limited Novel intermediates for linezolid and related compounds
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
MX2009008465A (es) 2007-02-15 2009-08-20 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos de taar1.
US7528131B2 (en) 2007-04-19 2009-05-05 Concert Pharmaceuticals Inc. Substituted morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
DE102007038251A1 (de) 2007-08-13 2009-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neues Herstellverfahren
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
WO2009045476A1 (en) 2007-10-02 2009-04-09 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
EP2212298B1 (en) 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
WO2009055006A1 (en) 2007-10-26 2009-04-30 Concert Pharmaceuticals, Inc. Deuterated darunavir
SI2215094T1 (sl) 2007-11-15 2016-05-31 Ym Biosciences Australia Pty Ltd N vsebujoče heterociklične spojine
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
FR2988722B1 (fr) * 2012-04-03 2014-05-09 Sanofi Sa Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques
RU2671494C2 (ru) * 2014-05-28 2018-11-01 Шанхай Фокон Фармасьютикал Ко., Лтд Некоторые ингибиторы протеинкиназы
CN105294737B (zh) * 2014-07-26 2019-02-12 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途

Also Published As

Publication number Publication date
RU2738837C2 (ru) 2020-12-17
CN109153686B (zh) 2021-04-30
EP3452484A1 (en) 2019-03-13
JP2019516790A (ja) 2019-06-20
MX2018013573A (es) 2019-08-01
ES2954148T3 (es) 2023-11-20
ZA201808238B (en) 2022-10-26
WO2017193872A1 (en) 2017-11-16
RU2018143284A3 (cg-RX-API-DMAC7.html) 2020-07-31
KR102374033B1 (ko) 2022-03-14
AU2017262155A1 (en) 2018-12-06
BR112018072699A2 (pt) 2019-02-19
JP6927548B2 (ja) 2021-09-01
CN109153686A (zh) 2019-01-04
CA3023460A1 (en) 2017-11-16
RU2018143284A (ru) 2020-06-08
US10835535B2 (en) 2020-11-17
EP3452484B1 (en) 2023-07-05
US20190209566A1 (en) 2019-07-11
AU2017262155B2 (en) 2021-03-11
TW201805290A (zh) 2018-02-16
KR20190025545A (ko) 2019-03-11
DK3452484T3 (da) 2023-09-25
EP3452484A4 (en) 2019-10-09
TWI752026B (zh) 2022-01-11

Similar Documents

Publication Publication Date Title
WO2017108723A3 (en) PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
EA201791692A1 (ru) 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
MD20150073A2 (ro) Derivaţi ai pirolo[2,3-d]pirimidinei ca inhibitori de Kinaze Janus-asociate (JAK)
MX2019008435A (es) Inhibidores selectivos de jak1.
MX381041B (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
MX389349B (es) Derivados de ácido borónico y usos terapéuticos de los mismos.
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
BR112018072168A2 (pt) compostos derivados da pirimidina como inibidores da quinase jak
EP4302830A3 (en) Quinazoline derivatives used to treat hiv
UY36265A (es) “derivados de pirrolo[2,3-d]pirimidina”.
MX374191B (es) Derivados de nucleósido sustituidos con 4´ -difluorometilo como inhibidores de la replicación de arn de la influenza.
MX381994B (es) Inhibidor de janus quinasa.
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
MX395032B (es) Ciertos inhibidores de la proteína quinasa.
MX2018008362A (es) Derivados de quinolin-2-ona.
CY1122423T1 (el) Παραγωγα πυριμιδινης χρησιμα ως εκλεκτικοι αναστολεις jak3 kai/ή jak1
TW201613938A (en) Selective inhibitors for protein kinases, a pharmaceutical composition and an use thereof
WO2016085221A3 (ko) 단백질 키나아제 저해제로 유용한 헤테로아릴아민 유도체
MX2019007339A (es) Compuestos de pirazolopirimidina y metodos de uso de los mismos.
EA201890821A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО[4,5-b]ПИРИДИНА В КАЧЕСТВЕ ДВОЙСТВЕННЫХ ИНГИБИТОРОВ DYRK1/CLK1
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).
MX2018013573A (es) Ciertos inhibidores de la proteína cinasa.
EA033106B1 (ru) Производное пуринил-n-гидроксипиримидинформамида, способы его получения и его применения